low bar inexpens compel
messi year unev in-lin guid
holx sale cc ahead street/our est
better diagnost breast health blood screen off-set
wors cynosur cyno gm decreas y/i ep
shi consensu y/i holx guid y/i pro forma
organ revenu growth exclud benefit deal headwind fx
well expect declin blood includ increment growth
recent deal roughli benefit exclud add
back organ sale growth said guid in-lin
ex blood estimate visibl alpha consensu ep expect grow
vs street estimate see
sale street season ep
also consensu due annual sale meet cost
increment cost recent deal overal guid line
low expect given linger cyno headwind link
better posit alreadi number
view guidanc isnt conserv expect mayb blood came
well guid look achiev given ou trend
runway tomo penetr us pick-up surgic solid growth
mdx panther util tick management note one larg contract renew
dgx/lh done pend cyno wild card expect
return growth view string disappoint tie
cyno seem better posit today howev updat model littl
chang except capit deploy mostli bake
see share fairli valu albeit discount peer reiter neutral rate
adjust est po reiter neutral rate
rais sale recent deal
ep est new po still base ep
estimate in-lin histor averag chang volatil risk rate high
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
lead manufactur medic
devic product focus heathcar need
mammographi breast biopsi earli stage
treatment remov uterin fibroid
compani acquir cynosur lead
medic aesthet compani larg portfolio
laser-bas product
core mammographi diagnost
busi deliv solid perform
especi ou market help
partial off-set issu relat
cynosur busi acquir continu
reserv cynosur
lack visibl concern although
po base approxim calendar ep estim impli
ev/ebitda in-line three-year histor averag
discount compani dx/medtech peer multipl
upsid risk po better-than-expect synergi cynosur
acquisit unreal benefit chang tax code faster growth
core diagnost mammographi gynecolog surgeri end market
downsid risk po
cynosur competit pressur slower uptak reimburs new product
unfavor chang clinic practic guidelin manag departur regulatori
risk faster declin legaci busi
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
